An Update of the Efficacy and Comparative Characteristics of Direct (New) Oral Anticoagulants (DOACs)
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Direct (New-generation) Oral Anticoagulants (DOACs) have emerged as effective agents which are used in place of vitamin-K antagonists in treatment and prophylaxis of Venous Thromboembolism (VTE), atrial fibrillation and other thrombotic diseases. Among them, the FIIa- direct thrombin inhibitor dabigatran and FXa inhibitors (rivaroxaban, apixaban, edoxaban) are the most broadly used. Anticoagulant dosing may differ under special considerations. The patients' physiological reserves, organ functional status and failures should be taken into account in clinical decision-making processes. The advantages and drawbacks of each specific agent should be weighed with special regard to metabolism, pharmacokinetics and pharmacodynamics, along with the efficiency of the agents in different indications. This article aims to review the most recent literature to highlight the usage and efficacy of the agents in different clinical conditions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Cardiovascular & hematological agents in medicinal chemistry - 20(2022), 2 vom: 14., Seite 114-124 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Karcioglu, Ozgur [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticoagulants |
|---|
| Anmerkungen: |
Date Completed 15.03.2022 Date Revised 31.05.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1871525719666210914112402 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330634321 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330634321 | ||
| 003 | DE-627 | ||
| 005 | 20231225211721.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1871525719666210914112402 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1102.xml |
| 035 | |a (DE-627)NLM330634321 | ||
| 035 | |a (NLM)34521333 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Karcioglu, Ozgur |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An Update of the Efficacy and Comparative Characteristics of Direct (New) Oral Anticoagulants (DOACs) |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2022 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Direct (New-generation) Oral Anticoagulants (DOACs) have emerged as effective agents which are used in place of vitamin-K antagonists in treatment and prophylaxis of Venous Thromboembolism (VTE), atrial fibrillation and other thrombotic diseases. Among them, the FIIa- direct thrombin inhibitor dabigatran and FXa inhibitors (rivaroxaban, apixaban, edoxaban) are the most broadly used. Anticoagulant dosing may differ under special considerations. The patients' physiological reserves, organ functional status and failures should be taken into account in clinical decision-making processes. The advantages and drawbacks of each specific agent should be weighed with special regard to metabolism, pharmacokinetics and pharmacodynamics, along with the efficiency of the agents in different indications. This article aims to review the most recent literature to highlight the usage and efficacy of the agents in different clinical conditions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Direct oral anticoagulants | |
| 650 | 4 | |a anticoagulation | |
| 650 | 4 | |a new oral anticoagulants | |
| 650 | 4 | |a thromboembolic disease. | |
| 650 | 4 | |a thrombosis | |
| 650 | 4 | |a venous thromboembolism | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Dabigatran |2 NLM | |
| 650 | 7 | |a I0VM4M70GC |2 NLM | |
| 700 | 1 | |a Yilmaz, Sarper |e verfasserin |4 aut | |
| 700 | 1 | |a Afacan, Göksu |e verfasserin |4 aut | |
| 700 | 1 | |a Ersan, Eylem |e verfasserin |4 aut | |
| 700 | 1 | |a Abuşka, Derya |e verfasserin |4 aut | |
| 700 | 1 | |a Zengin, Sehmus |e verfasserin |4 aut | |
| 700 | 1 | |a Ozkaya, Bilgen |e verfasserin |4 aut | |
| 700 | 1 | |a Hosseinzadeh, Mandana |e verfasserin |4 aut | |
| 700 | 1 | |a Yeniocak, Selman |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiovascular & hematological agents in medicinal chemistry |d 2006 |g 20(2022), 2 vom: 14., Seite 114-124 |w (DE-627)NLM161201482 |x 1875-6182 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2022 |g number:2 |g day:14 |g pages:114-124 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871525719666210914112402 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2022 |e 2 |b 14 |h 114-124 | ||